Measured Wealth Private Client Group LLC Sells 585 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Measured Wealth Private Client Group LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,977 shares of the biopharmaceutical company’s stock after selling 585 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Gilead Sciences were worth $365,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Tompkins Financial Corp boosted its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $29,000. Fortitude Family Office LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $29,000. Sachetta LLC bought a new position in Gilead Sciences during the fourth quarter worth about $30,000. Finally, Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 0.3 %

GILD stock opened at $68.40 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market capitalization of $85.22 billion, a price-to-earnings ratio of 190.00, a PEG ratio of 2.92 and a beta of 0.18. The business has a 50 day simple moving average of $66.01 and a two-hundred day simple moving average of $72.42.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.37 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.50%. Gilead Sciences’s payout ratio is presently 855.56%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. UBS Group cut their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Barclays cut their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Finally, Oppenheimer restated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average target price of $83.47.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.